First Advisor

Tugrul Daim

Date of Publication

Spring 5-17-2013

Document Type


Degree Name

Doctor of Philosophy (Ph.D.) in Technology Management


Engineering and Technology Management




Technological innovations -- Economic aspects -- China -- Case studies, Technology transfer -- China -- International cooperation -- Case studies, Pharmaceutical biotechnology industry -- China -- Case studies, Pharmaceutical biotechnology -- Technological innovations -- Case studies



Physical Description

1 online resource (xviii, 276 pages)


With the growing trend of globalization and rapid development of high technologies, emerging economies face more challenges in technology development because they are chasing a fast-moving frontier. They need to identify global technology trends and adapt to local needs and capabilities. Strategies for technology development differ among countries at different developmental stages.

In this research, a technology policy choice framework is developed to link prospective high-tech areas, technology development strategies, and various innovative resources. The research approach is to develop a hierarchical decision model (HDM) and apply the analytic hierarchical process (AHP). Experts are invited from diverse sources to provide a balanced perspective representing different stakeholders. This research focuses on the fast developing Chinese biopharmaceutical industry as a case study.

The results of this research have identified thirteen prospective biotech areas that China should invest more resources for development. These technology areas include: recombinant therapeutic proteins, recombinant vaccines, monoclonal antibody technology, cell and tissue engineering, gene therapy, antisense therapy, RNAi, nanobiotechnology, synthetic biology, bioinformatics, pharmacogenetics, gene sequencing, and biotechnology diagnostics. For most of these technology areas, the results have indicated an imitative innovation strategy should be taken as a better strategy under current technological conditions in China. The research has further found that high-tech small-to-medium companies and multinational corporations are major innovation contributors in the Chinese biopharmaceutical sector.

The research outcomes can serve as guidelines in resource allocation and policy making for technology development. Based on the overall research findings, policy-makers can apply more specific policy instruments to support innovation activities. Appropriate policy measures may help the country to construct an innovative ecosystem that can serve as the driving force for future technology development.


In Copyright. URI: This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

Persistent Identifier